TheEdgeResearch
Home / Stocks / IBER

Ibere Pharmaceuticals (IBER)

NYSE Financial Services Shell Companies
$10.18 ▼ -0.29%
Market Cap
$175.6M
Sector
Financial Services
Industry
Shell Companies
Beta
0.00
52-Wk Range
9.75-10.75
CEO
Osagie O. Imasogie
Country
US
Currency
USD

Ibere Pharmaceuticals operates in the Shell Companies industry of the Financial Services sector, headquartered in Philadelphia, PA, US. The stock last traded at $10.18, down 0.29% on the session, giving a market capitalisation of $175.6M. On trailing twelve-month figures it carries a trailing P/E of 29.94, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
29.94
Price / Sales
0.00
Price / Book
0.92
EV / EBITDA
-174.45
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.00
Current ratio
1.86
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange
Employees
IPO date
Headquarters
Philadelphia, PA, US
About Ibere Pharmaceuticals

Ibere Pharmaceuticals currently lacks significant operational activities, with its core mission focused on executing a business combination. This could involve a merger, an acquisition of assets or shares, or a corporate restructuring with one or more other entities. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.

Comparable companies

Ibere Pharmaceuticals is most often compared with the following Financial Services names:

APCABTWNFSNBLCWNFYSPRBMSLAMTRISVACQ
More research on IBER
IBER technical analysis IBER TheEdge Score Compare against peers
Open full interactive analysis & DCF →